These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 8561836)

  • 1. Evaluation of cycloserine in the treatment of Alzheimer's disease.
    Fakouhi TD; Jhee SS; Sramek JJ; Benes C; Schwartz P; Hantsburger G; Herting R; Swabb EA; Cutler NR
    J Geriatr Psychiatry Neurol; 1995 Oct; 8(4):226-30. PubMed ID: 8561836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved cognition in Alzheimer's disease with short-term D-cycloserine treatment.
    Tsai GE; Falk WE; Gunther J; Coyle JT
    Am J Psychiatry; 1999 Mar; 156(3):467-9. PubMed ID: 10080566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. d-Cycloserine enhances implicit memory in Alzheimer patients.
    Schwartz BL; Hashtroudi S; Herting RL; Schwartz P; Deutsch SI
    Neurology; 1996 Feb; 46(2):420-4. PubMed ID: 8614505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.
    Tariot PN; Cummings JL; Katz IR; Mintzer J; Perdomo CA; Schwam EM; Whalen E
    J Am Geriatr Soc; 2001 Dec; 49(12):1590-9. PubMed ID: 11843990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. D-cycloserine for Alzheimer's disease.
    Laake K; Oeksengaard AR
    Cochrane Database Syst Rev; 2002; 2002(2):CD003153. PubMed ID: 12076471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Once-weekly D-cycloserine effects on negative symptoms and cognition in schizophrenia: an exploratory study.
    Goff DC; Cather C; Gottlieb JD; Evins AE; Walsh J; Raeke L; Otto MW; Schoenfeld D; Green MF
    Schizophr Res; 2008 Dec; 106(2-3):320-7. PubMed ID: 18799288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. D-cycloserine for the treatment of ataxia in spinocerebellar degeneration.
    Ogawa M; Shigeto H; Yamamoto T; Oya Y; Wada K; Nishikawa T; Kawai M
    J Neurol Sci; 2003 Jun; 210(1-2):53-6. PubMed ID: 12736088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments.
    Buchanan RW; Javitt DC; Marder SR; Schooler NR; Gold JM; McMahon RP; Heresco-Levy U; Carpenter WT
    Am J Psychiatry; 2007 Oct; 164(10):1593-602. PubMed ID: 17898352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cognitive and quantified electroencephalographic correlates of cycloserine treatment in Alzheimer's disease.
    Mohr E; Knott V; Sampson M; Wesnes K; Herting R; Mendis T
    Clin Neuropharmacol; 1995 Feb; 18(1):28-38. PubMed ID: 8665532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of ABT-126 in Subjects with Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors: A Randomized, Double-Blind, Placebo-Controlled Study.
    Florian H; Meier A; Gauthier S; Lipschitz S; Lin Y; Tang Q; Othman AA; Robieson WZ; Gault LM
    J Alzheimers Dis; 2016; 51(4):1237-47. PubMed ID: 26967214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia.
    Heresco-Levy U; Ermilov M; Shimoni J; Shapira B; Silipo G; Javitt DC
    Am J Psychiatry; 2002 Mar; 159(3):480-2. PubMed ID: 11870017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Donepezil preserves cognition and global function in patients with severe Alzheimer disease.
    Black SE; Doody R; Li H; McRae T; Jambor KM; Xu Y; Sun Y; Perdomo CA; Richardson S
    Neurology; 2007 Jul; 69(5):459-69. PubMed ID: 17664405
    [TBL] [Abstract][Full Text] [Related]  

  • 13. D-cycloserine treatment of Alzheimer disease.
    Randolph C; Roberts JW; Tierney MC; Bravi D; Mouradian MM; Chase TN
    Alzheimer Dis Assoc Disord; 1994; 8(3):198-205. PubMed ID: 7986489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial.
    Wilcock GK; Black SE; Hendrix SB; Zavitz KH; Swabb EA; Laughlin MA;
    Lancet Neurol; 2008 Jun; 7(6):483-93. PubMed ID: 18450517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. D-Cycloserine Improves Difficult Discriminations in a Pattern Separation Task in Alzheimer's Disease Patients with Dementia.
    Goetghebeur PJD; Wesnes KA; Targum SD
    J Alzheimers Dis; 2019; 69(2):377-383. PubMed ID: 30958353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AMPA potentiator treatment of cognitive deficits in Alzheimer disease.
    Chappell AS; Gonzales C; Williams J; Witte MM; Mohs RC; Sperling R
    Neurology; 2007 Mar; 68(13):1008-12. PubMed ID: 17389305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
    Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial.
    Lannfelt L; Blennow K; Zetterberg H; Batsman S; Ames D; Harrison J; Masters CL; Targum S; Bush AI; Murdoch R; Wilson J; Ritchie CW;
    Lancet Neurol; 2008 Sep; 7(9):779-86. PubMed ID: 18672400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between pharmacodynamic activity and cognitive effects of eptastigmine in patients with Alzheimer's disease. Eptastigmine Study Group.
    Canal N; Imbimbo BP
    Clin Pharmacol Ther; 1996 Aug; 60(2):218-28. PubMed ID: 8823240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety, tolerability, and efficacy of PBT2 in Huntington's disease: a phase 2, randomised, double-blind, placebo-controlled trial.
    Huntington Study Group Reach2HD Investigators
    Lancet Neurol; 2015 Jan; 14(1):39-47. PubMed ID: 25467848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.